Payment overview · 2025
General Payments
$97.76
5 reported records · 4 companies
Healthcare provider profile · identity verified
Ukamaka N Nwadibia, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SIOUX FALLS, SD · NPI 1316280936
Verified facts
What the public records show
CMS Open Payments records show Ukamaka N Nwadibia, MD received $97.76 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.21 | 50.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.19 | 19.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.83 | 15.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.53 | 14.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.76 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 612 | 137 |
| Omeprazole | Omeprazole | 494 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 474 | 112 |
| Losartan Potassium | Losartan Potassium | 368 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 346 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 69 |
| Metformin Hcl | Metformin Hcl | 287 | 58 |
| Gabapentin | Gabapentin | 285 | 57 |
| Potassium Chloride | Potassium Chloride | 264 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 57 |
| Lisinopril | Lisinopril | 239 | 60 |
| Simvastatin | Simvastatin | 237 | 56 |
| Furosemide | Furosemide | 214 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 39 |
| Alendronate Sodium | Alendronate Sodium | 145 | 43 |
| Tramadol Hcl | Tramadol Hcl | 139 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 34 |
| Famotidine | Famotidine | 120 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 43 |
| Sertraline Hcl | Sertraline Hcl | 119 | 28 |
| Lorazepam | Lorazepam | 115 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 20 |
| Meloxicam | Meloxicam | 96 | 47 |
| Allopurinol | Allopurinol | 92 | 25 |
| Atenolol | Atenolol | 92 | 25 |
| Trazodone Hcl | Trazodone Hcl | 88 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 22 |
| Bupropion Xl | Bupropion Hcl | 85 | 18 |
| Pregabalin | Pregabalin | 81 | suppressed |
| Clonazepam | Clonazepam | 77 | 11 |
| Eliquis | Apixaban | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 18 |
| Mirtazapine | Mirtazapine | 73 | 12 |
| Jantoven | Warfarin Sodium | 70 | suppressed |
| Prednisone | Prednisone | 70 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 18 |
| Ozempic | Semaglutide | 66 | 15 |
| Spironolactone | Spironolactone | 64 | 14 |
| Jardiance | Empagliflozin | 63 | 11 |
| Glimepiride | Glimepiride | 61 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 60 | 14 |
| Montelukast Sodium | Montelukast Sodium | 57 | 12 |
| Metformin Hcl Er | Metformin Hcl | 56 | 13 |
| Glipizide | Glipizide | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 27 |
| Carvedilol | Carvedilol | 47 | 14 |
| Amoxicillin | Amoxicillin | 45 | 17 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Irbesartan | Irbesartan | 43 | 11 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Sodium Bicarbonate | Sodium Bicarbonate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 30 |
| Fluconazole | Fluconazole | 34 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Ondansetron Odt | Ondansetron | 34 | 12 |
| Azithromycin | Azithromycin | 33 | 32 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Estradiol | Estradiol | 29 | 13 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 19 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Temazepam | Temazepam | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.76 · 5 records | Amgen Inc. | Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, NURTEC ODT, REPATHA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error